Clinical cancer genomics: How soon is now? Journal Article
| Authors: | Taylor, B. S.; Ladanyi, M. |
| Article Title: | Clinical cancer genomics: How soon is now? |
| Abstract: | Germline and somatic alterations in DNA mediate the genesis and progression of human cancers. Not only do these events represent the molecular underpinnings of disease but many are of immense clinical importance as diagnostic markers and therapeutic targets. In fact, rapidly evolving sequencing technologies have empowered enormous growth in the breadth and depth of cancer genome characterization. Whether these will impact routine clinical practice and the treatment of disease is no longer debatable, but how precisely this will happen is a source of ongoing speculation and development. Copyright © 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. |
| Keywords: | gene mutation; review; erlotinib; clinical practice; gastrointestinal stromal tumor; imatinib; cancer susceptibility; epidermal growth factor receptor; genotype; chronic myeloid leukemia; cetuximab; colorectal carcinoma; tumor suppressor gene; human genome; gene fusion; genomics; clinical decision making; dna sequence; familial cancer; cancer epidemiology; bcr abl protein; cancer tissue; nilotinib; k ras protein; tumor gene; transcriptome; tumor classification; b raf kinase; sequencing; genotyping; mutation detection; personalized therapy |
| Journal Title: | Journal of Pathology |
| Volume: | 223 |
| Issue: | 2 |
| ISSN: | 0022-3417 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2011-01-01 |
| Start Page: | 318 |
| End Page: | 326 |
| Language: | English |
| DOI: | 10.1002/path.2794 |
| PROVIDER: | scopus |
| PUBMED: | 21125684 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 1" - "Export Date: 4 March 2011" - "CODEN: JPTLA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work